Substance / Medication

Rezafungin

Overview

Active Ingredient
rezafungin
RxNorm CUI
2639155
Labeler: Melinta Therapeutics, LLCUpdated: 2025-12-23T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

REZZAYO is contraindicated in patients with known hypersensitivity to rezafungin or other echinocandins.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

7 trials linked to this intervention

7
Total Trials
0
Recruiting
5
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Rezafungin vs caspofungin for the treatment of invasive candidiasis: A systematic review and meta-analysis.
Al Diab Al Azzawi Mohammad, Abdat Wejdan, Alhamed Arina et al. · Diagn Microbiol Infect Dis · 2025
PMID: 40651396Meta-Analysis
Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy.
Sofjan Amelia K, Mitchell Ardath, Shah Dhara N et al. · J Glob Antimicrob Resist · 2018
PMID: 29486356Meta-Analysis
Development of a rezafungin isolate verification panel and comparison of reference method to ThermoFisher Sensititre YeastOne panel MIC results.
DiFranco-Fisher Jeanna, Koeth Laura · Diagn Microbiol Infect Dis · 2026
PMID: 40944997Observational
Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials.
Thompson George R, Soriano Alex, Honore Patrick M et al. · Lancet Infect Dis · 2024
PMID: 38008099Observational
Multicentre validation of a modified EUCAST MIC testing method and development of associated epidemiologic cut-off (ECOFF) values for rezafungin.
Arendrup Maiken Cavling, Arikan-Akdagli Sevtap, Castanheira Mariana et al. · J Antimicrob Chemother · 2022
PMID: 36329639Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Rezafungin (substance)
SNOMED CT
1363064008
UMLS CUI
C4726687
RxNorm CUI
2639155
Labeler
Melinta Therapeutics, LLC

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
7
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.